Loading…
← CockpitCompetitor Analysis › ANAB AnaptysBio, Inc.Open in the cockpit ↗

AnaptysBio, Inc.ANABCompetitor analysis, valuation and peers

United States · USD·Health Care›Biotechnology

Develops antibody therapies for inflammatory disease and earns royalties on antibodies it discovered and licensed to partners.

Momentum weak 34
Mkt cap
$1.40B
US dollars, full cap
Free float
93%
of shares outstanding
$/day
$17.8M
20-day average traded
Fwd P/E
4.9×
forward earnings
ROIC−WACC
+63.5 pp
WACC 8.8%
Hurdle
-25 pp
Req g minus delivered
Close · USD$47.06
1D+3.2%
1W-3.5%
1M+3.6%
3M-17.0%
6M-21.7%
YTD+45.6%
1Y+103.0%
ATR %4.3%
Beta1.05
52w lowhigh35.0% off high

What AnaptysBio does

Develops antibody therapies for inflammatory disease and earns royalties on antibodies it discovered and licensed to partners.

Does not sell a medicine itself: its income is a royalty on GSK's sales of Jemperli, a cancer antibody it discovered, plus milestone payments, which it uses to fund its own inflammatory-disease pipeline.

Products and services

  • Royalty-bearing partnered antibodies (e.g. Jemperli via GSK)
  • Internal antibody pipeline

Customers

  • Pharma licensees including GSK

Where it sits in the supply chain

  • Health Care
  • Biotechnology
  • Antibody discovery for inflammatory…

What could go right

  • Growing royalty stream from partnered drugs
  • Internal pipeline progression

What could go wrong

  • Dependence on partner drug commercial success for royalties
  • Spun off its lead internal asset into a separate company in 2026

Moat: narrow (IP / patents, process know-how). Proprietary antibody generation platform has produced multiple partnered, royalty-bearing approved drugs.

Headquarters: San Diego, California, US · Founded: 2005 · Employees: 104

Named competitors

AnaptysBio at a glance

Size AnaptysBio (ANAB) is a United States Health Care company (Biotechnology) with a market value of $1.40B, the 2014th largest of 3,085 United States companies the cockpit tracks. Shares closed at $47.06 on 18 Nov 2026.

Performance Over six months the shares fell 21.7%, against -17.2% for the median peer and -2.2% for the United States market (cap-weighted) — 7th lowest of 19 in its peer set.

Growth Revenue grew 13.0% over the last twelve months (peer median +28.0%); the operating margin is 62.2% (peer median -296.1%).

Valuation It trades at 4.9× forward earnings against a peer median of 134.6× (cheapest of 6).

Price implies For today's price to make sense, revenue must grow about 0% a year for seven years (Req g). Recent delivered growth is +26%, so the hurdle is -25 pp: the price already allows for a slowdown.

Capital Return on invested capital runs 63.5 points above its cost of capital (8.8% WACC).

Short interest Short interest is 16.9% of the free float (30 Oct 2026).

Relative performance

8010012021 May 202621 Aug 202618 Nov 2026Peer median 80ANAB 78
Six months, rebased to 100: AnaptysBio against the median of its 20 peers (local-currency closes).

AnaptysBio financials

Reported figures in USD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue$192M$235M$91.3M$17.2M$10.3M
Revenue growth—+157%+432%+67%—
Gross profitn/a$232M$88.9M$14.8M$7.95M
EBITDA$121M$50.3M-$113M-$155M-$113M
Net income$184M-$13.2M-$145M-$164M-$129M
Free cash flow$35.9M$19.6M-$136M-$122M-$74.0M
Capital expenditure$1,000$87,000$358,000$807,000$358,000
Total debt$262M$291M$369M$329M$324M

Quarterly statements and history in the cockpit →

AnaptysBio competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

0%+100%+200%-25%0%+25%+50%RAPPABSI688185QURE6881054588IMCRTYRA688765NUVBMSB087010NVAXANAB6-month return →1-month return →
Up and to the right = strong over both horizons. AnaptysBio is the large dot.

Fundamentals: revenue growth against valuation

0%+100%0×100×200×688185688105URGN2637NVAXANABRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. AnaptysBio is the large dot.

AnaptysBio competitors and peer comparison

Head to head with its named competitors (ANAB vs ABBV vs GMAB.CO vs XNCR)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
AnaptysBio ANAB$1.40B-22%+13%62%4.9×0.5%
AbbVie ABBV$506B+35%+11%36%18.1×-0.1%
Genmab A/S GMAB.CO$30.8B+103%+15%31%40.9×11.6%
Xencor XNCR$2.58B+204%+34%-73%n/an/a

How AnaptysBio compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

AnaptysBio against its 20 peers (data as of 18 Nov 2026)
MeasureANABPeer medianRank in peer set
1-month return+3.6%-15.3%2nd highest of 21
6-month return-21.7%-17.2%7th lowest of 19
Distance from 52-week high-35.0%-47.0%5th highest of 21
Revenue growth (TTM)+13.0%+28.0%7th lowest of 18
Operating margin62.2%-296.1%highest of 19
Forward P/E4.9×134.6×cheapest of 6
Growth the price implies (Req g, 7 yrs)0.5%n/a—
Growth delivered (Del g)+25.6%n/a—
Hurdle (Req g minus delivered)-25.1 ppn/a—
ROIC minus cost of capital+63.5 pp-23.7 pphighest of 9
EV / EBITDA12.4×n/a—
Net debt / EBITDA0.9×n/a—

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
AnaptysBio ANABUnited States$1.40B-22%+13%62%4.9×0.5%+25.6%
Rapport Therapeutics RAPPUnited States$1.39B-34%n/a-838%n/an/an/a
Absci ABSIUnited States$1.41B+65%-47%-9,155%n/an/an/a
CanSino Biologics 688185.SSChina$1.38B0%+30%-4%199.3×n/an/a
uniQure QUREUnited States$1.42B-17%+28%-1,027%n/an/an/a
Nanjing Vazyme Biotech 688105.SSChina$1.42B+25%+16%-5%137.8×39.4%-2.5%
Oncolys BioPharma 4588.TJapan$1.37B+181%+1,749%-295%n/an/an/a
Intellia Therapeutics NTLAUnited States$1.37B-20%-8%-821%n/an/an/a
Immunocore Holdings Plc Shs Sponsored American Depositary Shares Repr 1 Sh IMCRUnited States$1.44B-7%+13%-7%n/an/an/a
Tyra Bioscience TYRAUnited States$1.35B-41%n/an/an/an/an/a
Wuhan Healthgen Biotechnology 688765.SSChina$1.46B-51%+90%-297%n/an/an/a
Generate Biomedicines GENBUnited States$1.34B-20%+56%-737%n/an/an/a
UroGen Pharma URGNUnited States$1.46B-1%+159%-12%16.7×n/an/a
Nuvation Bio NUVBUnited States$1.34B-16%+654%-61%n/an/an/a
Fujian Haixi Pharmaceuticals 2637.HKHong Kong$1.47B-32%+25%33%46.4×n/an/a
Zhuhai Trinomab Pharmaceutical 688806.SSChina$1.32Bn/a+238%-1,196%n/an/an/a
Mesoblast MSB.AXAustralia$1.49B-17%+556%-43%n/an/an/a
Peptron 087010.KSSouth Korea$1.49B-68%-13%-488%n/an/an/a
Novavax NVAXUnited States$1.31B-14%-61%-17%134.6×n/an/a
TLC BioSciences 7924.TWOTaiwan$1.50Bn/an/an/an/an/an/a
Taysha Gene Therapies TSHAUnited States$1.30B-27%-13%-2,998%n/an/an/a

Questions

Who are AnaptysBio's main competitors?
Named competitors: AbbVie (ABBV), Genmab (GMAB.CO), Xencor (XNCR). The cockpit's measured peer set (industry) also includes Rapport Therapeutics (RAPP), Absci (ABSI), CanSino Biologics (688185.SS), uniQure (QURE), Nanjing Vazyme Biotech (688105.SS), Oncolys BioPharma (4588.T).
Is AnaptysBio expensive compared with its peers?
On forward p/e it trades at 4.9× against a peer median of 134.6×, cheapest of 6 in its peer set. For today's price to make sense, revenue must grow about 0% a year for seven years (Req g). Recent delivered growth is +26%, so the hurdle is -25 pp: the price already allows for a slowdown.
How has AnaptysBio stock performed?
Over six months to 18 Nov 2026 the shares returned -21.7% against -17.2% for the median peer; over one year +103.0%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.